Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
7 "Diabetes complications"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Review Article
Diabetes, obesity and metabolism
The Impact of Taurine on Obesity-Induced Diabetes Mellitus: Mechanisms Underlying Its Effect
Kainat Ahmed, Ha-Neul Choi, Jung-Eun Yim
Endocrinol Metab. 2023;38(5):482-492.   Published online October 17, 2023
DOI: https://doi.org/10.3803/EnM.2023.1776
  • 2,011 View
  • 139 Download
  • 1 Crossref
AbstractAbstract PDFPubReader   ePub   
This review explores the potential benefits of taurine in ameliorating the metabolic disorders of obesity and type 2 diabetes (T2D), highlighting the factors that bridge these associations. Relevant articles and studies were reviewed to conduct a comprehensive analysis of the relationship between obesity and the development of T2D and the effect of taurine on those conditions. The loss of normal β-cell function and development of T2D are associated with obesity-derived insulin resistance. The occurrence of diabetes has been linked to the low bioavailability of taurine, which plays critical roles in normal β-cell function, anti-oxidation, and anti-inflammation. The relationships among obesity, insulin resistance, β-cell dysfunction, and T2D are complex and intertwined. Taurine may play a role in ameliorating these metabolic disorders through different pathways, but further research is needed to fully understand its effects and potential as a therapeutic intervention.

Citations

Citations to this article as recorded by  
  • Effect of a Very Low-Calorie Diet on Oxidative Stress, Inflammatory and Metabolomic Profile in Metabolically Healthy and Unhealthy Obese Subjects
    Neus Bosch-Sierra, Carmen Grau-del Valle, Christian Salom, Begoña Zaragoza-Villena, Laura Perea-Galera, Rosa Falcón-Tapiador, Susana Rovira-Llopis, Carlos Morillas, Daniel Monleón, Celia Bañuls
    Antioxidants.2024; 13(3): 302.     CrossRef
Close layer
Original Articles
Diabetes, Obesity and Metabolism
Effect of the Concomitant Use of Subcutaneous Basal Insulin and Intravenous Insulin Infusion in the Treatment of Severe Hyperglycemic Patients
Yejee Lim, Jung Hun Ohn, Joo Jeong, Jiwon Ryu, Sun-wook Kim, Jae Ho Cho, Hee-Sun Park, Hye Won Kim, Jongchan Lee, Eun Sun Kim, Nak-Hyun Kim, You Hwan Jo, Hak Chul Jang
Endocrinol Metab. 2022;37(3):444-454.   Published online June 3, 2022
DOI: https://doi.org/10.3803/EnM.2021.1341
  • 3,991 View
  • 235 Download
  • 2 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
No consensus exists regarding the early use of subcutaneous (SC) basal insulin facilitating the transition from continuous intravenous insulin infusion (CIII) to multiple SC insulin injections in patients with severe hyperglycemia other than diabetic ketoacidosis. This study evaluated the effect of early co-administration of SC basal insulin with CIII on glucose control in patients with severe hyperglycemia.
Methods
Patients who received CIII for the management of severe hyperglycemia were divided into two groups: the early basal insulin group (n=86) if they received the first SC basal insulin 0.25 U/kg body weight within 24 hours of CIII initiation and ≥4 hours before discontinuation, and the delayed basal insulin group (n=79) if they were not classified as the early basal insulin group. Rebound hyperglycemia was defined as blood glucose level of >250 mg/dL in 24 hours following CIII discontinuation. Propensity score matching (PSM) methods were additionally employed for adjusting the confounding factors (n=108).
Results
The rebound hyperglycemia incidence was significantly lower in the early basal insulin group than in the delayed basal insulin group (54.7% vs. 86.1%), despite using PSM methods (51.9%, 85.2%). The length of hospital stay was shorter in the early basal insulin group than in the delayed basal insulin group (8.5 days vs. 9.6 days, P=0.027). The hypoglycemia incidence did not differ between the groups.
Conclusion
Early co-administration of basal insulin with CIII prevents rebound hyperglycemia and shorten hospital stay without increasing the hypoglycemic events in patients with severe hyperglycemia.

Citations

Citations to this article as recorded by  
  • 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024
    Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Rodolfo J. Galindo, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J.
    Diabetes Care.2024; 47(Supplement): S295.     CrossRef
  • 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2023
    Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, Raveendhara R. Bannuru, Florence M. Brown, Dennis Bruemmer, Billy S. Collins, Marisa E. Hilliard, Diana Isaacs, Eric L. Johnson, Scott Kahan, Kamlesh Khunti, Jose Leon, Sarah K. Lyons, Mary Lou Perry, Priya
    Diabetes Care.2023; 46(Supplement): S267.     CrossRef
  • Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial
    Kitti Thammakosol, Chutintorn Sriphrapradang
    Diabetes, Obesity and Metabolism.2023; 25(3): 815.     CrossRef
Close layer
Clinical Study
Association of Vitamin D Deficiency with Diabetic Nephropathy
So-hyeon Hong, Young Bin Kim, Hoon Sung Choi, Tae-Dong Jeong, Jin Taek Kim, Yeon Ah Sung
Endocrinol Metab. 2021;36(1):106-113.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2020.826
  • 8,294 View
  • 220 Download
  • 20 Web of Science
  • 22 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Low 25-hydroxyvitamin D (25OHD) levels are associated with the incidence of type 2 diabetes mellitus (T2DM). However, the association between 25OHD and metabolic health status or diabetic complications is inconclusive. We evaluated this relationship between vitamin D status and metabolic parameters and complications of T2DM.
Methods
This study included 1,392 patients with T2DM who visited Eulji and Ewha Diabetes Center between January 2011 and August 2016. Anthropometric parameters and laboratory tests including glycated hemoglobin (HbA1c), lipid profile, liver and kidney function, and urinary albumin-to-creatinine ratio (UACR) were evaluated. Diabetic macro- and microvascular complications were determined through a medical record review. Serum 25OHD concentrations were measured by chemiluminescent immunoassay.
Results
The mean 25OHD level was 16.8±9.6 ng/mL. Vitamin D deficiency (<20 ng/mL) and severe deficiency (<10 ng/mL) were observed in 990 (71.1%) and 351 (25.2%) participants, respectively. 25OHD level was positively correlated with age and highdensity lipoprotein cholesterol (HDL-C) level and negatively correlated with HbA1c, triglyceride level, and UACR. HDL-C and UACR were significantly associated with 25OHD after adjusting for other variables. Vitamin D deficiency was independently related to nephropathy after adjusting for confounding variables.
Conclusion
Vitamin D deficiency was common among Korean T2DM patients; it was independently associated with microalbuminuria and HDL level, and positively related to diabetic nephropathy.

Citations

Citations to this article as recorded by  
  • ED-71 ameliorates bone regeneration in type 2 diabetes by reducing ferroptosis in osteoblasts via the HIF1α pathway
    Maoshan Wang, Yingxue Liu, Houda Gui, Gaoqiang Ma, Binyang Li, Zhanwei Zhang, Gyeonghwi Yu, Ailin Wu, Xin Xu, Dongjiao Zhang
    European Journal of Pharmacology.2024; 969: 176303.     CrossRef
  • Vitamin D metabolism in diabetic nephropathy
    Z. V. Abilov, R. Kh. Salimkhanov, A. A. Povaliaeva, A. Yu. Zhukov, E. A. Pigarova, L. K. Dzeranova, L. Ya. Rozhinskaya
    Obesity and metabolism.2024; 20(4): 283.     CrossRef
  • COVID-19 infection and metabolic comorbidities: Mitigating role of nutritional sufficiency and drug – nutraceutical combinations of vitamin D
    Sumit Kumar Mandal, Meghana Tare, P.R. Deepa
    Human Nutrition & Metabolism.2023; 31: 200179.     CrossRef
  • Effects of Vitamin D Supplementation in Diabetic Kidney Disease: A Systematic Review
    Thais de Oliveira e Silva Ullmann, Beatrys Juliani Ramalho, Lucas Fornari Laurindo, Ricardo José Tofano, Claudio José Rubira, Elen Landgraf Guiguer, Sandra Maria Barbalho, Uri Adrian Prync Flato, Katia Portero Sloan, Adriano Cressoni Araujo
    Journal of Renal Nutrition.2023; 33(5): 618.     CrossRef
  • Diabetic Nephropathy: Significance of Determining Oxidative Stress and Opportunities for Antioxidant Therapies
    Marina Darenskaya, Sergey Kolesnikov, Natalya Semenova, Lyubov Kolesnikova
    International Journal of Molecular Sciences.2023; 24(15): 12378.     CrossRef
  • Association between serum 25- hydroxyvitamin D and albuminuiria in middle-aged and older Chinese patients with type 2 diabetes
    Luyan Zhang, Qian Guo, Yanjia Xu, Wenzhen Wei, Yu Wang
    BMC Endocrine Disorders.2023;[Epub]     CrossRef
  • Vitamin D deficiency and its associated factors among patients with type 2 diabetes mellitus: a systematic review and meta-analysis
    Mitku Mammo Taderegew, Gashaw Garedew Woldeamanuel, Alemayehu Wondie, Atsede Getawey, Abera Nesiru Abegaz, Fentahun Adane
    BMJ Open.2023; 13(10): e075607.     CrossRef
  • Progression of diabetic nephropathy and vitamin D serum levels: A pooled analysis of 7722 patients
    Yomna E. Dean, Sameh Samir Elawady, Wangpan Shi, Ahmed A. Salem, Arinnan Chotwatanapong, Haya Ashraf, Tharun Reddi, Prashant Obed Reddy Dundi, Waleed Yasser Habash, Mohamed Yasser Habash, Safaa Ahmed, Hana M. Samir, Ahmed Elsayed, Aryan Arora, Abhinav Aro
    Endocrinology, Diabetes & Metabolism.2023;[Epub]     CrossRef
  • Incidence of Vitamin D Deficiency and Its Association With Microalbuminuria in Patients With Type 2 Diabetes Mellitus
    Muhammad Hamza Riaz, Ammar Jamil, Hira Yousaf, Muhammad Hassan, Muhammad Ahmer Sohaib, Sharjeel Babar, Muhammad Hassan Ahmad, Ibtesam Allahi, Muhammad Zeshan Mehmood, Tayyab Mumtaz Khan
    Cureus.2023;[Epub]     CrossRef
  • The Role of Vitamin D in Diabetic Nephropathy: A Translational Approach
    Charlotte Delrue, Reinhart Speeckaert, Joris R. Delanghe, Marijn M. Speeckaert
    International Journal of Molecular Sciences.2022; 23(2): 807.     CrossRef
  • Associations of serum amyloid A and 25‐hydroxyvitamin D with diabetic nephropathy: A cross‐sectional study
    Qian Liu, Jin Sun, Tongdao Xu, Guangrong Bian, Fumeng Yang
    Journal of Clinical Laboratory Analysis.2022;[Epub]     CrossRef
  • Formulation Strategies for Improving the Stability and Bioavailability of Vitamin D-Fortified Beverages: A Review
    Elsa F. Vieira, Suene Souza
    Foods.2022; 11(6): 847.     CrossRef
  • Association between Vitamin D Status and Mortality among Adults with Diabetic Kidney Disease
    Feng Xu, Hongyu Lu, Tianwen Lai, Ling Lin, Yongsong Chen, Pratibha V. Nerurkar
    Journal of Diabetes Research.2022; 2022: 1.     CrossRef
  • Assessment of the relationship between 25-hydroxyvitamin D and albuminuria in type 2 diabetes mellitus
    Seyed Alireza Zomorodian, Maryam Shafiee, Zeinab Karimi, Fatemeh Masjedi, Amirhossein Roshanshad
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
  • Association of Serum 25 (OH) Vitamin D With Chronic Kidney Disease Progression in Type 2 Diabetes
    Suyan Duan, Fang Lu, Buyun Wu, Chengning Zhang, Guangyan Nie, Lianqin Sun, Zhimin Huang, Honglei Guo, Bo Zhang, Changying Xing, Yanggang Yuan
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • The Influence of Dietary Supplementations on Neuropathic Pain
    Francesco D’Egidio, Giorgia Lombardozzi, Housem E. Kacem Ben Haj M’Barek, Giada Mastroiacovo, Margherita Alfonsetti, Annamaria Cimini
    Life.2022; 12(8): 1125.     CrossRef
  • Emergence of Ectopic Adrenal Tissues-What are the Probable Mechanisms?
    Gürkan Tarçın, Oya Ercan
    Journal of Clinical Research in Pediatric Endocrinology.2022; 14(3): 258.     CrossRef
  • Nutritional Supplements for the Treatment of Neuropathic Pain
    Khaled M. Abdelrahman, Kevin V. Hackshaw
    Biomedicines.2021; 9(6): 674.     CrossRef
  • Vitamin D Deficiency as a Predictor of a High Prevalence of Coronary Artery Disease in Pancreas Transplant Candidates With Type 1 Diabetes
    Małgorzata Buksińska-Lisik, Przemysław J. Kwasiborski, Robert Ryczek, Wojciech Lisik, Artur Mamcarz
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Serum 25-hydroxyvitamin D and Metabolic Parameters in Healthy Korean Adults: Korean National Health and Nutrition Examination Survey VI
    Jeonghoon Ha, Hansang Baek, Chaiho Jeong, Hyunsam Kim, Ki-Hyun Baek, Moo Il Kang, Dong-Jun Lim
    International Journal of General Medicine.2021; Volume 14: 5233.     CrossRef
  • Association Between 25(OH)Vitamin D, HbA1c and Albuminuria in Diabetes Mellitus: Data From a Population-Based Study (VIDAMAZON)
    João Soares Felício, Hana Andrade de Rider Britto, Pedro Celeira Cortez, Fabrício de Souza Resende, Manuela Nascimento de Lemos, Lorena Vilhena de Moraes, Vitória Teixeira de Aquino, Fernanda de Souza Parente, Natércia Neves Marques de Queiroz, João Felíc
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Vitamin D Analogs Can Retard the Onset or Progression of Diabetic Kidney Disease: A Systematic Review
    Samuel N. Uwaezuoke
    Frontiers in Clinical Diabetes and Healthcare.2021;[Epub]     CrossRef
Close layer
Clinical Study
Current Management of Type 2 Diabetes Mellitus in Primary Care Clinics in Korea
Da Hea Seo, Shinae Kang, Yong-ho Lee, Jung Yoon Ha, Jong Suk Park, Byoung-Wan Lee, Eun Seok Kang, Chul Woo Ahn, Bong-Soo Cha
Endocrinol Metab. 2019;34(3):282-290.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.282
  • 5,848 View
  • 83 Download
  • 15 Web of Science
  • 15 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

This study investigated the overall status of diabetes control and screening for diabetic microvascular complications in patients with type 2 diabetes mellitus attending primary care clinics in Korea.

Methods

In this cross-sectional observational study, 191 primary care clinics were randomly selected across Korea from 2015 to 2016. In total, 3,227 subjects were enrolled in the study.

Results

The patients followed at the primary care clinics were relatively young, with a mean age of 61.4±11.7 years, and had a relatively short duration of diabetes (mean duration, 7.6±6.5 years). Approximately 14% of subjects had diabetic microvascular complications. However, the patients treated at the primary care clinics had suboptimal control of hemoglobin A1c levels, blood pressure, and serum lipid levels, along with a metabolic target achievement rate of 5.9% according to the Korean Diabetes Association guidelines. The screening rates for diabetic nephropathy, retinopathy, and neuropathy within the past 12 months were 28.4%, 23.3%, and 13.3%, respectively.

Conclusion

The overall status of diabetes management, including the frequency of screening for microvascular complications, was suboptimal in the primary care clinics. More efforts should be made and more resources need to be allocated for primary care physicians to promote adequate healthcare delivery, which would result in stricter diabetes control and improved management of diabetic complications.

Citations

Citations to this article as recorded by  
  • Risk of Cause-Specific Mortality across Glucose Spectrum in Elderly People: A Nationwide Population-Based Cohort Study
    Joonyub Lee, Hun-Sung Kim, Kee-Ho Song, Soon Jib Yoo, Kyungdo Han, Seung-Hwan Lee
    Endocrinology and Metabolism.2023; 38(5): 525.     CrossRef
  • Comparison of on-Statin Lipid and Lipoprotein Levels for the Prediction of First Cardiovascular Event in Type 2 Diabetes Mellitus
    Ji Yoon Kim, Jimi Choi, Sin Gon Kim, Nam Hoon Kim
    Diabetes & Metabolism Journal.2023; 47(6): 837.     CrossRef
  • Effectiveness of quality of care for patients with type 2 diabetes in China: findings from the Shanghai Integration Model (SIM)
    Chun Cai, Yuexing Liu, Yanyun Li, Yan Shi, Haidong Zou, Yuqian Bao, Yun Shen, Xin Cui, Chen Fu, Weiping Jia
    Frontiers of Medicine.2022; 16(1): 126.     CrossRef
  • Comparison of Health Outcomes by Care Provider Type for Newly Diagnosed Mild Type 2 Diabetes Patients in South Korea: A Retrospective Cohort Study
    Hee-Chung Kang, Jae-Seok Hong
    Healthcare.2022; 10(2): 334.     CrossRef
  • Management Status of Patients with Type 2 Diabetes Mellitus at General Hospitals in Korea: A 5-Year Follow-Up Study
    Jin Hee Jung, Jung Hwa Lee, Hyang Mi Jang, Young Na, Hee Sun Choi, Yeon Hee Lee, Yang Gyo Kang, Na Rae Kim, Jeong Rim Lee, Bok Rye Song, Kang Hee Sim
    The Journal of Korean Diabetes.2022; 23(1): 64.     CrossRef
  • Type 2 Diabetes Mellitus with Early Dry Skin Disorder: A Comparison Study Between Primary and Tertiary Care in Indonesia
    Lili Legiawati, Kusmarinah Bramono, Wresti Indriatmi, Em Yunir, Aditya Indra Pratama
    Current Diabetes Reviews.2022;[Epub]     CrossRef
  • Long-Term Changes in HbA1c According to Blood Glucose Control Status During the First 3 Months After Visiting a Tertiary University Hospital
    Hyunah Kim, Da Young Jung, Seung-Hwan Lee, Jae-Hyoung Cho, Hyeon Woo Yim, Hun-Sung Kim
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Differences in health behavior and nutrient intake status between diabetes-aware and unaware Korean adults based on the Korea national health and nutrition examination survey 2016–18 data: A cross-sectional study
    Anshul Sharma, Chen Lulu, Kee-Ho Song, Hae-Jeung Lee
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • Effects of Diabetes Quality Assessment on Diabetes Management Behaviors Based on a Nationwide Survey
    Chang Kyun Choi, Jungho Yang, Ji-An Jeong, Min-Ho Shin
    International Journal of Environmental Research and Public Health.2022; 19(23): 15781.     CrossRef
  • The Impact of the Indonesian Chronic Disease Management Program (PROLANIS) on Metabolic Control and Renal Function of Type 2 Diabetes Mellitus Patients in Primary Care Setting
    Firas Farisi Alkaff, Fauzan Illavi, Sovia Salamah, Wiwit Setiyawati, Ristra Ramadhani, Elly Purwantini, Dicky L. Tahapary
    Journal of Primary Care & Community Health.2021; 12: 215013272098440.     CrossRef
  • Questionnaire-based Survey of Demographic and Clinical Characteristics, Health Behaviors, and Mental Health of Young Korean Adults with Early-Onset Diabetes
    Ji In Park, Hyunjeong Baek, Sang-Wook Kim, Ji Yun Jeong, Kee-Ho Song, Ji Hee Yu, Il Sung Nam-Goong, Eun-Hee Cho
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score–Matched Cohort Study
    Min-Kyung Lee, Bongsung Kim, Kyungdo Han, Jae-Hyuk Lee, Minhee Kim, Mee Kyoung Kim, Ki-Hyun Baek, Ki-Ho Song, Hyuk-Sang Kwon, Young-Jung Roh
    Diabetes Care.2021; 44(10): 2419.     CrossRef
  • Challenges in the Management of Diabetes in Primary Care
    Yeon Kyung Lee
    The Journal of Korean Diabetes.2020; 21(3): 161.     CrossRef
  • Does Diabetes Increase the Risk of Contracting COVID-19? A Population-Based Study in Korea
    Sung-Youn Chun, Dong Wook Kim, Sang Ah Lee, Su Jung Lee, Jung Hyun Chang, Yoon Jung Choi, Seong Woo Kim, Sun Ok Song
    Diabetes & Metabolism Journal.2020; 44(6): 897.     CrossRef
  • Comprehensive Efforts Are Needed to Improve the Quality of Primary Diabetes Care in Korea
    Chan-Hee Jung
    Endocrinology and Metabolism.2019; 34(3): 265.     CrossRef
Close layer
Diabetes
Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Jae Hyun Bae, Sunhee Kim, Eun-Gee Park, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
Endocrinol Metab. 2019;34(1):80-92.   Published online March 21, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.1.80
  • 7,377 View
  • 264 Download
  • 36 Web of Science
  • 38 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

To investigate the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal outcomes in patients with type 2 diabetes.

Methods

MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched to identify randomized controlled trials (RCTs) of DPP-4 inhibitors from inception to September 2017. We selected eligible RCTs comparing DPP-4 inhibitors with placebo or other antidiabetic agents and reporting at least one renal outcome. A meta-analysis was conducted to calculate standardized mean differences, weighted mean differences (WMDs), relative risks (RRs), and 95% confidence intervals (CIs) for each renal outcome.

Results

We included 23 RCTs with 19 publications involving 41,359 patients. Overall changes in urine albumin-to-creatinine ratio were comparable between DPP-4 inhibitors and controls (P=0.150). However, DPP-4 inhibitors were associated with significantly lower risk of incident microalbuminuria (RR, 0.89; 95% CI, 0.80 to 0.98; P=0.022) and macroalbuminuria (RR, 0.77; 95% CI, 0.61 to 0.97; P=0.027), as well as higher rates of regression of albuminuria (RR, 1.22; 95% CI, 1.10 to 1.35; P<0.001) compared with controls. Although DPP-4 inhibitors were associated with small but significantly lower estimated glomerular filtration rate (WMD, −1.11 mL/min/1.73 m2; 95% CI, −1.78 to −0.44; P=0.001), there was no difference in the risk of end-stage renal disease between two groups (RR, 0.93; 95% CI, 0.76 to 1.14; P=0.475).

Conclusion

DPP-4 inhibitors had beneficial renal effects mainly by reducing the risk of development or progression of albuminuria compared with placebo or other antidiabetic agents.

Citations

Citations to this article as recorded by  
  • Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study
    Mototsugu Nagao, Jun Sasaki, Kyoko Tanimura-Inagaki, Ichiro Sakuma, Hitoshi Sugihara, Shinichi Oikawa
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
  • Effects of glucose‐lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta‐analysis of randomized controlled trials with external adjudication of events
    Edoardo Mannucci, Marco Gallo, Andrea Giaccari, Riccardo Candido, Basilio Pintaudi, Giovanni Targher, Matteo Monami
    Diabetes, Obesity and Metabolism.2023; 25(2): 444.     CrossRef
  • Sitagliptin Mitigates Diabetic Nephropathy in a Rat Model of Streptozotocin-Induced Type 2 Diabetes: Possible Role of PTP1B/JAK-STAT Pathway
    Sarah M. AL-Qabbaa, Samaher I. Qaboli, Tahani K. Alshammari, Maha A. Alamin, Haya M. Alrajeh, Lama A. Almuthnabi, Rana R. Alotaibi, Asma S. Alonazi, Anfal F. Bin Dayel, Nawal M. Alrasheed, Nouf M. Alrasheed
    International Journal of Molecular Sciences.2023; 24(7): 6532.     CrossRef
  • Take an individualized and multipronged approach when managing older adults with type 2 diabetes
    Sheridan M. Hoy
    Drugs & Therapy Perspectives.2023; 39(5): 171.     CrossRef
  • Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials
    Awadhesh Kumar Singh, Akriti Singh, Ritu Singh
    Endocrine Practice.2023; 29(7): 509.     CrossRef
  • Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based study
    Cheuk To Chung, Ishan Lakhani, Oscar Hou In Chou, Teddy Tai Loy Lee, Edward Christopher Dee, Kenrick Ng, Wing Tak Wong, Tong Liu, Sharen Lee, Qingpeng Zhang, Bernard Man Yung Cheung, Gary Tse, Jiandong Zhou
    Cancer Medicine.2023; 12(11): 12299.     CrossRef
  • Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes
    Deborah J. Wexler, Ian H. de Boer, Alokananda Ghosh, Naji Younes, Ionut Bebu, Silvio E. Inzucchi, Janet B. McGill, Sunder Mudaliar, David Schade, Michael W. Steffes, William V. Tamborlane, Meng H. Tan, Faramarz Ismail-Beigi, Jill P. Crandall, Melissa Dian
    JAMA Internal Medicine.2023; 183(7): 705.     CrossRef
  • SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
    M. Ganeva
    Trakia Journal of Sciences.2023; 21(1): 54.     CrossRef
  • Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
    Christian W. Mende
    Advances in Therapy.2022; 39(1): 148.     CrossRef
  • Management of Hyperglycemia in Older Adults with Type 2 Diabetes
    Gunjan Y. Gandhi, Arshag D. Mooradian
    Drugs & Aging.2022; 39(1): 39.     CrossRef
  • Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review
    Zhen Ruan, Huimin Zou, Qing Lei, Carolina Oi Lam Ung, Honghao Shi, Hao Hu
    Expert Review of Pharmacoeconomics & Outcomes Research.2022; 22(4): 555.     CrossRef
  • Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial
    Hiroki Teragawa, Takeshi Morimoto, Yuichi Fujii, Tomohiro Ueda, Mio Sakuma, Michio Shimabukuro, Osamu Arasaki, Koichi Node, Takashi Nomiyama, Shinichiro Ueda
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 685.     CrossRef
  • Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs
    Hyo Jin Kim, Sang Soo Kim, Sang Heon Song
    The Korean Journal of Internal Medicine.2022; 37(3): 502.     CrossRef
  • The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus
    Wan-Chia Hsu, Chun-Sheng Lin, Jung-Fu Chen, Chih-Min Chang
    Journal of Clinical Medicine.2022; 11(9): 2653.     CrossRef
  • Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
    Hiroaki Yagyu, Hitoshi Shimano
    Journal of Diabetes Investigation.2022; 13(9): 1472.     CrossRef
  • Finerenone, a Novel and Safer Approach toward Management of Diabetic Kidney Disease with Heart Failure
    Ayesha Abdul Qadir Memon, Sarmad Iqbal
    Global Journal of Medical, Pharmaceutical, and Biomedical Update.2022; 17: 12.     CrossRef
  • The effects of dipeptidyl peptidase‐4 inhibitors on kidney outcomes
    Daniel V. O'Hara, Thomas R. Parkhill, Sunil V. Badve, Min Jun, Meg J. Jardine, Vlado Perkovic
    Diabetes, Obesity and Metabolism.2021; 23(3): 763.     CrossRef
  • Urinary DPP4 correlates with renal dysfunction, and DPP4 inhibition protects against the reduction in megalin and podocin expression in experimental CKD
    Acaris Benetti, Flavia Letícia Martins, Letícia Barros Sene, Maria Heloisa M. Shimizu, Antonio C. Seguro, Weverton M. Luchi, Adriana C. C. Girardi
    American Journal of Physiology-Renal Physiology.2021; 320(3): F285.     CrossRef
  • Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists
    Johannes F.E. Mann, Marcel H.A. Muskiet
    Kidney International.2021; 99(2): 314.     CrossRef
  • Renoprotective Effects of DPP-4 Inhibitors
    Daiji Kawanami, Yuichi Takashi, Hiroyuki Takahashi, Ryoko Motonaga, Makito Tanabe
    Antioxidants.2021; 10(2): 246.     CrossRef
  • Danegaptide Prevents TGFβ1-Induced Damage in Human Proximal Tubule Epithelial Cells of the Kidney
    Paul E. Squires, Gareth W. Price, Ulrik Mouritzen, Joe A. Potter, Bethany M. Williams, Claire E. Hills
    International Journal of Molecular Sciences.2021; 22(6): 2809.     CrossRef
  • Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
    Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
    Endocrinology and Metabolism.2021; 36(2): 388.     CrossRef
  • Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Jack Wei Chieh Tan, David Sim, Junya Ako, Wael Almahmeed, Mark E Cooper, Jamshed J Dalal, Chaicharn Deerochanawong, David Wei Chun Huang, Sofian Johar, Upendra Kaul, Sin Gon Kim, Natalie Koh, Alice Pik-Shan Kong, Rungroj Krittayaphong, Bernard Kwok, Bien
    European Cardiology Review.2021;[Epub]     CrossRef
  • Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
    Francesco Prattichizzo, Paola de Candia, Antonio Ceriello
    Metabolism.2021; 120: 154799.     CrossRef
  • SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease
    Robert C. Stanton
    Seminars in Nephrology.2021; 41(2): 85.     CrossRef
  • Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
    Nina Vodošek Hojs, Sebastjan Bevc, Robert Ekart, Nejc Piko, Tadej Petreski, Radovan Hojs
    Pharmaceuticals.2021; 14(6): 561.     CrossRef
  • Podocyte Glucocorticoid Receptors Are Essential for Glomerular Endothelial Cell Homeostasis in Diabetes Mellitus
    Swayam Prakash Srivastava, Han Zhou, Ocean Setia, Alan Dardik, Carlos Fernandez‐Hernando, Julie Goodwin
    Journal of the American Heart Association.2021;[Epub]     CrossRef
  • Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease
    Swayam Prakash Srivastava, Rohit Srivastava, Subhash Chand, Julie E. Goodwin
    Pharmaceuticals.2021; 14(8): 751.     CrossRef
  • Effects of DPP4 inhibitors on renal outcomes in diabetes mellitus: A systematic review and meta-analysis
    SaikatK Dalui, Raja Chakraverty, Nafisha Yasmin, Smita Pattanaik, Kaushik Pandit, Suparna Chatterjee
    Indian Journal of Endocrinology and Metabolism.2021; 25(4): 283.     CrossRef
  • Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting
    Yueh-Ting Lee, Chien-Ning Hsu, Chung-Ming Fu, Shih-Wei Wang, Chiang-Chi Huang, Lung-Chih Li
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • The Role of DPP-4 Inhibitors in Type-2 Diabetes Patients with Chronic Kidney Disease
    Mishal Yousef Alqurashi, Khalid Faisal Alharthi, Abdulaziz Abdulrahman Alshehri, Yazeed Khalid Alharbi, Mohammad Abdulmunem Sanousi, Anas Abdullah Almazyed, Khulud Saeed Alghamdi, Sarah Musaad Alrashidi, Waad Abdullah Qaeed, Amjad Aedh Alasmari
    Pharmacophore.2021; 12(3): 91.     CrossRef
  • Type 2 diabetes mellitus management in patients with chronic kidney disease: an update
    Zoi Kleinaki, Stella Kapnisi, Sofia-Andriani Theodorelou-Charitou, Ilias P. Nikas, Stavroula A. Paschou
    Hormones.2020; 19(4): 467.     CrossRef
  • Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
    David M. Williams, Asif Nawaz, Marc Evans
    Diabetes Therapy.2020; 11(2): 369.     CrossRef
  • Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
    Shih-Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, Rong-Nan Chien, Ming-Jui Hung, Yuk-Ying Chan, Yea-Huei Kao Yang, Edward Chia-Cheng Lai
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Novel therapeutic agents for the treatment of diabetic kidney disease
    Rachel E. Hartman, P.S.S. Rao, Mariann D. Churchwell, Susan J. Lewis
    Expert Opinion on Investigational Drugs.2020; 29(11): 1277.     CrossRef
  • Renal protection with glucagon-like peptide-1 receptor agonists
    Martina Vitale, Jonida Haxhi, Tiziana Cirrito, Giuseppe Pugliese
    Current Opinion in Pharmacology.2020; 54: 91.     CrossRef
  • Loss of Mitochondrial Control Impacts Renal Health
    Swayam Prakash Srivastava, Keizo Kanasaki, Julie E. Goodwin
    Frontiers in Pharmacology.2020;[Epub]     CrossRef
  • Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
    Scientific Reports.2019;[Epub]     CrossRef
Close layer
Review Article
Diabetes
Evolution of Diabetes Care in Hong Kong: From the Hong Kong Diabetes Register to JADE-PEARL Program to RAMP and PEP Program
Ivy H.Y. Ng, Kitty K.T. Cheung, Tiffany T.L. Yau, Elaine Chow, Risa Ozaki, Juliana C.N. Chan
Endocrinol Metab. 2018;33(1):17-32.   Published online March 21, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.1.17
  • 4,888 View
  • 65 Download
  • 15 Web of Science
  • 12 Crossref
AbstractAbstract PDFPubReader   ePub   

The rapid increase in diabetes prevalence globally has contributed to large increases in health care expenditure on diabetic complications, posing a major health burden to countries worldwide. Asians are commonly observed to have poorer β-cell function and greater insulin resistance compared to the Caucasian population, which is attributed by their lower lean body mass and central obesity. This “double phenotype” as well as the rising prevalence of young onset diabetes in Asia has placed Asians with diabetes at high risk of cardiovascular and renal complications, with cancer emerging as an important cause of morbidity and mortality. The experience from Hong Kong had demonstrated that a multifaceted approach, involving team-based integrated care, information technological advances, and patient empowerment programs were able to reduce the incidence of diabetic complications, hospitalizations, and mortality. System change and public policies to enhance implementation of such programs may provide solutions to combat the burgeoning health problem of diabetes at a societal level.

Citations

Citations to this article as recorded by  
  • Impact of Body Composition and Anemia on Accuracy of a Real-Time Continuous Glucose Monitor in Diabetes Patients on Continuous Ambulatory Peritoneal Dialysis
    James Ling, Jack K.C. Ng, Eric S.H. Lau, Andrea O.Y. Luk, Ronald C.W. Ma, Robert A. Vigersky, Philip K.T. Li, Juliana C.N. Chan, Cheuk Chun Szeto, Elaine Chow
    Diabetes Technology & Therapeutics.2024; 26(1): 70.     CrossRef
  • Levels and correlates of risk factor control in diabetes mellitus –ELSA-Brasil
    Bruna Cristine Chwal, Rodrigo Citton Padilha dos Reis, Maria Inês Schmidt, Bruce B. Duncan, Sandhi Maria Barreto, Rosane Harter Griep
    Diabetology & Metabolic Syndrome.2023;[Epub]     CrossRef
  • Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study
    Xinrong Zhang, Terry Cheuk‐Fung Yip, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Guanlin Li, Huapeng Lin, Lilian Yan Liang, Jimmy Che‐To Lai, Mandy Sze‐Man Lai, Johnny T. K. Cheung, Henry Lik‐Yuen Chan, Stephen Lam Chan, Alice Pik‐Shan Kong, Grace Lai‐Hung Wong, Vinc
    Alimentary Pharmacology & Therapeutics.2023; 57(10): 1103.     CrossRef
  • Team-Based Diabetes Care in Ontario and Hong Kong: a Comparative Review
    Calvin Ke, Emaad Mohammad, Juliana C. N. Chan, Alice P. S. Kong, Fok-Han Leung, Baiju R. Shah, Douglas Lee, Andrea O. Luk, Ronald C. W. Ma, Elaine Chow, Xiaolin Wei
    Current Diabetes Reports.2023; 23(7): 135.     CrossRef
  • Team-Based Approach to Reduce Malignancies in People with Diabetes and Obesity
    Ziyue Zhu, Samuel Yeung Shan Wong, Joseph Jao Yiu Sung, Thomas Yuen Tung Lam
    Current Diabetes Reports.2023; 23(10): 253.     CrossRef
  • Professor Juliana Chung Ngor Chan: Tireless Trailblazer for Diabetes Research, Care, and Education in Asia
    Ronald C.W. Ma, Wing Yee So, Andrea O.Y. Luk
    Diabetes Care.2022; 45(10): 2207.     CrossRef
  • Predicting the Development of Myocardial Infarction in Middle-Aged Adults with Type 2 Diabetes: A Risk Model Generated from a Nationwide Population-Based Cohort Study in Korea
    Seung-Hwan Lee, Kyungdo Han, Hun-Sung Kim, Jae-Hyoung Cho, Kun-Ho Yoon, Mee Kyoung Kim
    Endocrinology and Metabolism.2020; 35(3): 636.     CrossRef
  • From Hong Kong Diabetes Register to JADE Program to RAMP-DM for Data-Driven Actions
    Juliana C.N. Chan, Lee-Ling Lim, Andrea O.Y. Luk, Risa Ozaki, Alice P.S. Kong, Ronald C.W. Ma, Wing-Yee So, Su-Vui Lo
    Diabetes Care.2019; 42(11): 2022.     CrossRef
  • Cholesterol levels and development of cardiovascular disease in Koreans with type 2 diabetes mellitus and without pre-existing cardiovascular disease
    Mee Kyoung Kim, Kyungdo Han, Han Na Joung, Ki-Hyun Baek, Ki-Ho Song, Hyuk-Sang Kwon
    Cardiovascular Diabetology.2019;[Epub]     CrossRef
  • Effects of Variability in Blood Pressure, Glucose, and Cholesterol Concentrations, and Body Mass Index on End-Stage Renal Disease in the General Population of Korea
    Mee Kyoung Kim, Kyungdo Han, Hun-Sung Kim, Yong-Moon Park, Hyuk-Sang Kwon, Kun-Ho Yoon, Seung-Hwan Lee
    Journal of Clinical Medicine.2019; 8(5): 755.     CrossRef
  • Efficacy and safety of fixed‐dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double‐blind, controlled, phase 3 trial
    Ji Cheol Bae, Kyung Wan Min, Yong Hyun Kim, Kyoung‐Ah Kim, Eun‐Gyoung Hong, Cheol‐Young Park, Song Han, Bong‐Soo Cha
    Diabetes, Obesity and Metabolism.2019; 21(1): 103.     CrossRef
  • Statin Use is Associated with Decreased Hepatocellular Carcinoma Recurrence in Liver Transplant Patients
    Yongin Cho, Myoung Soo Kim, Chung Mo Nam, Eun Seok Kang
    Scientific Reports.2019;[Epub]     CrossRef
Close layer
Original Article
Multi-country Study on the Prevalence and Clinical Features of Peripheral Arterial Disease in Type 2 Diabetic Patients Who are at High Risk for Atherosclerosis.
Sang Youl Rhee, Seungjoon Oh, Young Kil Choi, Doo Man Kim, Bong Yun Cha, Hyun Chul Lee, Seung Woo Ha, In Kyu Lee, Tae Sun Park, Min Young Chung, In Joo Kim, Moon Kyu Lee, Sung Soo Koong, Kyung Soo Park, Kyung Wan Min, Young Seol Kim
J Korean Endocr Soc. 2006;21(4):290-301.   Published online August 1, 2006
DOI: https://doi.org/10.3803/jkes.2006.21.4.290
  • 1,846 View
  • 26 Download
AbstractAbstract PDF
BACKGROUND
PAD-SEARCH (Peripheral Arterial Disease-Screening and Evaluation of diabetic patients in Asian Regions Characterized by High risk factors) is the first international study to investigate the prevalence of peripheral arterial disease (PAD) in Asian type 2 diabetic patients and to demonstrate the relationships between the putative risk factors and PAD in this population. METHODS: A total of 6,625 type 2 diabetic patients (2,873 males and 3,752 females aged 50 and older) were enrolled in PAD-SEARCH in Korea, China, Taiwan, Hong Kong, Indonesia, Thailand and Philippines from October 2003 to March 2004. The Fukuda vascular profile VS-1000(TM) was used to determine the ankle-brachial index (ABI) and the brachial-ankle pulse wave velocity (baPWV). RESULTS: The mean patient age was 63.7 +/- 8.2 years and the mean duration of diabetes was 10.3 +/- 8.0 years. 1,172 (17.7%) subjects were diagnosed as PAD by the ABI (< or = 0.9). Subjects with PAD had a significantly longer duration of diabetes or hypertension, a higher HbA1c level and a significantly lower mean BMI than did the non-PAD subjects. In terms of the lipid profiles, triglyceride was the only significant variable. Notably, the mean ABI and baPWV in the females were significantly poorer than the age matched males for the in subjects with a normal ABI. However, the mean ABI and baPWV in males were significantly poorer than those of the age matched females for the subjects with PAD. On the multivariate analysis, gender, age, BMI, smoking status, duration of diabetes and a previous history of cerebrovascular disease were identified as the independent risk factors of PAD. CONCLUSION: These findings suggest that PAD is a common complication in Asian type 2 diabetic patients. Therefore, PAD screening and treatment should be emphasized for Asian diabetic patients with high risk factors.
Close layer

Endocrinol Metab : Endocrinology and Metabolism